We use cookies to ensure that we give you the best experience on our website Learn more
Apr 1, 2016
26th European Congress of Clinical Microbiology and Infectious DiseasesLow rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX™, a post hoc analysis of two pivotal phase 3 trials
;Zoran Popmihajlov;
Lei Pang;
Elizabeth Brown;
Shu-Chih Su;
Susan Kaplan;
English Willis
zoster vaccine live
shingles vaccine
zostavax
herpes zoster
vaccine
Oh no! This abstract is missing. Is this your research? Get in touch at support@morressier.com
or log in to the world's largest platform for early-stage research
Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.
Keywords
zoster vaccine live
shingles vaccine
zostavax
herpes zoster
vaccine
Company
Legal
Follow us
© Copyright 2019 Morressier GmbH. All rights reserved.